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Epilepsy is a chronic disorder characterized by spontaneous recurrent seizures. Brain inflammation is increasingly recognized as a
critical factor for seizure precipitation, but the molecular mediators of such proconvulsant effects are only partly understood. The
chemokine CCL2 is one of themost elevated inflammatorymediators in patients with pharmacoresistent epilepsy, but its contribution to
seizure generation remains unexplored. Here, we show, for the first time, a crucial role for CCL2 and its receptor CCR2 in seizure control.
We imposed a systemic inflammatory challenge via lipopolysaccharide (LPS) administration inmicewithmesial temporal lobe epilepsy.
We found that LPS dramatically increased seizure frequency and upregulated the expression of many inflammatory proteins, including
CCL2. To test the proconvulsant role of CCL2, we administered systemically either a CCL2 transcription inhibitor (bindarit) or a selective
antagonist of the CCR2 receptor (RS102895).We found that interference with CCL2 signaling potently suppressed LPS-induced seizures.
Intracerebral administration of anti-CCL2 antibodies also abrogated LPS-mediated seizure enhancement in chronically epileptic
animals. Our results reveal that CCL2 is a keymediator in the molecular pathways that link peripheral inflammation with neuronal
hyperexcitability.
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Introduction
Inflammatory processes within the brain parenchyma are well-
known determinants of seizure propensity (Fabene et al., 2008;
Friedman and Dingledine, 2011; Pernot et al., 2011; de Vries et
al., 2012; Devinsky et al., 2013; Vezzani et al., 2013). In particular,
seizures upregulate inflammatory mediators in animal models,
and increased levels of many cytokines/chemokines such as
interleukin-1 (IL-1) and C-C motif ligand 2 (CCL2; also
known as monocyte chemoattractant protein-1, MCP-1) can be
detected in brain tissue of patients with intractable epilepsy
(Aronica and Gorter, 2007; Choi et al., 2009). Importantly, brain
inflammatory pathways play a key role in recurrence and precip-
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Significance Statement
Substantial evidence points to a role for inflammation in epilepsy, but currently there is little insight as to how inflammatory
pathways impact on seizure generation. Here, we examine themolecularmediators linking peripheral inflammation with seizure
susceptibility inmicewithmesial temporal lobe epilepsy.We show that a systemic inflammatory challenge via lipopolysaccharide
administration potently enhances seizure frequency and upregulates the expression of the chemokine CCL2. Remarkably, selec-
tive pharmacological interference with CCL2 or its receptor CCR2 suppresses lipopolysaccharide-induced seizure enhancement.
Thus, CCL2/CCR2 signaling plays a key role in linking systemic inflammation with seizure susceptibility.
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itation of seizures (Vezzani et al., 2000; Maroso et al., 2010). For
example, IL-1 causes potent proconvulsant effects bymediating
enhanced calcium influx through NMDA receptors (Vezzani et
al., 2013).
Peripheral inflammatory stimuli can also impact on seizure
propensity. Clinical and experimental data provide solid evi-
dence for a role of systemic infection in triggering or sustaining
seizures (Cross, 2012; Marchi et al., 2014). Specifically, systemic
inflammation reduces the threshold for pharmacologically in-
duced acute seizures in animals (Sayyah et al., 2003; Riazi et al.,
2008), and this has been linked to upregulation of proinflamma-
tory cytokines (Riazi et al., 2008).
A systemic inflammatory challenge during a critical period in
early development leaves a lasting impact on brain excitability
and seizure susceptibility later in life (Galic et al., 2008). Periph-
eral inflammatory stimuli trigger a local brain inflammatory
“mirror” reaction (i.e., cytokine and chemokine production)
similar to the response elicited in the periphery (Perry and Hol-
mes, 2014). The diseased brain displays an amplified, exaggerated
response to a systemic inflammatory challenge, as a result of glial
activation and “priming” (Perry and Holmes, 2014).
We have exploited a systemic inflammatory challenge in ani-
mals with chronic mesial temporal lobe epilepsy (MTLE) to
identify novelmolecular pathways involved in seizure regulation.
Microarray and ELISA analyses indicated a potential role for the
chemokine CCL2 in mediating seizure upregulation following
systemic LPS. Accordingly, functional blocking experiments
highlighted a crucial role for CCL2 in inflammation-induced
seizures.
Materials andMethods
Animals. Experiments were conducted in accord with the European
Community Directive 2010/63/EU and were approved by the Italian
Ministry of Health. Animals were housed in a 12 h light/dark cycle with
food and water available ad libitum. Adult (8–12 weeks old) C57BL/6N
male mice were used in all experiments. All efforts were made to mini-
mize animal suffering.
Kainic acid (KA) injection and placement of electrodes. Mice were uni-
laterally injected with 50 nl of a 20mM solution of KA in PBS into the left
dorsal hippocampus under Hypnorm/Hypnovel anesthesia (Antonucci
et al., 2008, 2009). Stereotaxic injections into the dorsal blade of the
dentate gyrus were made at the following coordinates with respect to
bregma: anteroposterior 2.0, mediolateral 1.5, 1.7 mm below dura.
Mice were then implanted with a bipolar electrode inserted into the
injected hippocampus. The bipolar electrode was formed of two enamel-
insulated nichrome wires (120m). A ground electrode was placed over
the cerebellum. Electrodes were connected to a multipin socket and se-
cured to the skull by acrylic dental cement. In a subset of animals, a guide
cannula was glued to the bipolar electrode and positioned on top of dura
for anti-CCL2 or control IgG injection.
EEG recordings.EEG recordingswere performed in freelymovingmice
during the chronic phase of epilepsy. In all animals, recordings began
between 15 and 21 d after KA. All mice were recorded for 1 h daily during
baseline periods. Mice were then intraperitoneally injected with LPS
(L5886, Sigma; from Salmonella enterica, serotype abortus equi; 100
g/kg in PBS, n 7) or saline (n 7). Additional EEG recording sessions
(2 h long) were made 2 and 24 h after treatment. For bindarit experi-
ments, after a baseline recording period (4–5 d), bindarit (100 mg/kg in
0.5% methylcellulose [MC]; n  10 mice) or MC (0.5% in aqueous
solution; n 11mice) was daily intraperitoneally injected for 4 d. Thirty
minutes after the third and the fourth injection, EEG activity was re-
corded for 30 min. On the fourth day, mice received an intraperitoneal
injection of LPS, and EEG recordings were performed between 2 and 4 h
after the systemic challenge. The choice of bindarit dose (100mg/kg) was
based on our previous studies, showing that a similar dose was able to
reduce CCL2 expression in the brain and suppress neuropathological
signs of experimental autoimmune encephalomyelitis in vivo (Ge et al.,
2012).
To interfere with signaling via the CCL2 receptor, we injected system-
ically a selective CCR2 antagonist (RS102895; 5 mg/kg, Tocris Biosci-
ence; n 7) or vehicle (4%DMSO in saline; n 7) as control. Injections
of RS102895/vehicle were given twice (i.e., immediately after and 1.5 h
following LPS delivery in chronically epileptic animals). RS102895 has
been previously used as a potent and specific antagonist of CCR2 (Hung
et al., 2013; Ren et al., 2015).
In anti-CCL2 experiments, after a baseline recording period (2–3 d),
mice were injected with goat anti-CCL2 (1 l of a 100 g/ml solution;
AF-479-NA, R&D Systems; n 7) or control goat IgG (AB-108-C, R&D
Systems; n 6) via the implantedmicrocannula. This blocking antibody
has been previously shown to efficiently neutralize the biological activity
of CCL2 in vitro and in vivo (e.g., Stamatovic et al., 2006; Fujimoto et al.,
2009). One hour after injection, mice received an intraperitoneal LPS
injection and EEG recordingswere performed between 2 and 4 h after the
systemic challenge.
All recordings were performed between 10:00 A.M. and 6:00 P.M., and
care was taken to record from each animal at the same time of the day.
Signals were amplified (10,000-fold), bandpass filtered (0.3–100 Hz),
digitized (National Instruments card), and conveyed to a computer for
storage and analysis (Antonucci et al., 2008, 2009; Mainardi et al., 2012).
Detection of seizures was performed with custom software written in
LabView (National Instruments). The program first identified spikes in
the EEG using a voltage threshold. This voltage threshold was set to 4.5
times the SD of the EEG signal (determined in a period devoid of spike
activity). Spontaneous recurrent seizures (SRSs) were defined as spike
clusters lasting for 4 s, whereas clusters lasting 4 s and isolated spi-
kes were considered as interictal events. For each recording session, we
determined the frequency and duration of SRS and interictal clusters, the
number of single spikes, and the total time spent in seizures or in inter-
ictal activity (calculated by adding together the duration of either ictal or
interictal episodes) (Antonucci et al., 2008, 2009; Mainardi et al., 2012;
Vannini et al., 2015). For histological controls, naive and chronically
epileptic animals were deeply anesthetized and perfused with 4% PFA.
Serial coronal sections (40 m) throughout the dorsal hippocampus
were processed for Nissl staining.
Tissue dissections for molecular analyses. To analyze mRNA expression
changes by microarray and qRT-PCR, KA-injected hippocampi were
dissected from epileptic mice during the chronic phase, 4 and 24 h after
LPS or saline intraperitoneal administration. For CCL2 mRNA in situ
hybridization andCCL2/CCR2 immunohistochemistry, brains were dis-
sected fromKA-treated epileptic mice during the chronic phase, 4 h after
LPS administration. For ELISA experiments, hippocampi were dissected
from chronically epileptic and naive animals, 4 h after LPS or saline
administration; at the same time, serum was collected by cardiac punc-
ture from each animal. For ELISA experiments, two additional groups of
nonepileptic, naive animals received LPS (100 g/kg in PBS) or saline
and tissues were collected 4 h after treatment. In bindarit experiments,
epileptic mice received daily intraperitoneal injection of bindarit or MC
for 4 d. On the fourth day, 1 h after bindarit or MC administration, mice
were challengedwith LPS.Hippocampal tissues and bloodwere collected
4 h after LPS delivery. RS102895 was administered immediately after and
1.5 h following LPS delivery in chronically epileptic animals (see above)
and hippocampi were collected 4 h after LPS.
Table 1. Primers used for qRT-PCR experiments
Gene Forward primer (5-3) Reverse primer (5-3) GenBank #
CCL12 CTACCACCATCAGTCCTC TGAATCTTCTGCTTAACAACAT NM011331
CCL2 GAGTAGGCTGGAGAGCTACAAGAG AGGTAGTGGATGCATTAGCTTCAG NM11333
CCL4 CTCTCTCCTCTTGCTCGT GGTCTCATAGTAATCCATCACAA NM013652
CCL5 AGAATACATCAACTATTTGGAGA CCTTGCATCTGAAATTTTAATGA NM013653
CCR2 CCAGTAAATGCCATGCAAGTTC CCGTGGATGAACTGAGGTAAC NM009915
CXCL10 GACCATCAAGAATTTAATGAAAGCG CCATCCACTGGGTAAAGGG NM021274
IL1 ACGGACCCCAAAAGATGAAG TTCTCCACAGCCACAATGAG NM008361
TLR2 TGATGGTGAAGGTTGGACG CGGAGGGAATAGAGGTGAAAG NM011905
TLR4 TTCAGAACTTCAGTGGCTGG TGTTAGTCCAGAGAAACTTCCTG NM021297
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Microarray analysis. RNAs from dissected hippocampi (n  4 per
experimental group) were purified using standard column purification
according to themanufacturer’s protocol (RNAeasyMiniKit,QIAGEN).
RNA quality was analyzed by microfluidic gel electrophoresis on RNA
6000 NanoChips using the Agilent 2100 Bioanalyzer. Only RNA with a
high (9) RNA integrity number was selected and used for subsequent
retrotranscription, labeling, and array hybridization according toAgilent
protocols. Mouse gene expression arrays (Agilent 4  44K slides) were
hybridized and scanned with the Agilent microarray station. Intensity
values were processed with GeneSpring GX software (Agilent) using de-
fault parameters to remove low-quality probes (Sgado` et al., 2013). Sig-
nals were then normalized by means of the quantile normalization
method, and data were statistically filtered by two-way ANOVA impos-
ing a fold change2 for each gene in at least one of the four experimental
data groups. Differentially expressed genes were classified by DAVID
software, applying Benjamini-corrected p value cutoff of 0.05. Gene clas-
sification was performed according the Kyoto Encyclopedia of Genes
and Genomes (KEGG; http://www.genome.jp/kegg/), Panther Molec-
ular Function (http://www.pantherdb.org/panther/ontologies.jsp), and
GOterm Molecular Function (http://geneontology.org) databases.
Figure 1. Histopathological changes and EEG seizures in the KAmodel ofMTLE.A, Nissl staining in coronal sections froma naivemouse (top) and fromamouse killed 21 d after intrahippocampal
KA (bottom). In the epileptic hippocampus, note the typical granule cell dispersion and extensive neuronal loss in CA1 and CA3. Scale bar, 500m. B, Representative EEG recordings displaying
activity in thehippocampusduring the chronicphaseof epilepsy. Three typesof epileptiformevents aredistinguished: seizures (spike clusters lasting for4 s; a, red), interictal clusters (spike clusters
lasting4 s; b, green), and isolated spikes (c, blue).
Figure 2. Impact of LPS challenge on the epileptic brain. A, Representative intrahippocampal EEG recordings from chronically epileptic mice, before and 2–4 h after saline/LPS administration.
LPS clearly increases SRS frequency. B, Number of EEG seizures per 10 min of recording in epileptic mice, before and after saline (black circles) or LPS (red circles). Seizure frequency is significantly
enhanced by LPS (two-way repeated-measures ANOVA followed by Holm–Sidak test, p 0.05). C, Total time spent in ictal activity per 10 min of recording. Epileptic animals treated with LPS
significantly spentmore time in ictal activity than saline-injectedmice (two-way repeated-measures ANOVA followedbyHolm–Sidak test,p0.05).D,Meanduration of EEG seizures in saline- and
LPS-treatedmice (onewayANOVA; p 0.7). E, Total time spent in interictal activity per 10min of recording. Epileptic animals treatedwith LPS (red circles) significantly spentmore time in interictal
activity than saline-injectedmice (black circle) 2– 4 h following the systemic challenge (two-way repeated-measures ANOVA followed by Holm–Sidak test, p 0.05). F, Number of isolated spikes
per 10 min of recordings. No difference was found between LPS and saline-injected epileptic mice (two-way repeated-measures ANOVA followed by Holm–Sidak test, p 0.5). Data are SEM.
*p 0.05.
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qRT-PCR. Total RNAs were extracted by Trizol reagent (Invitrogen)
from explanted hippocampi (n  4 mice per experimental group).
DNase-treated RNAs were purified by RNA extraction RNAeasy Kit
(QIAGEN). cDNA was synthesized from pooled RNAs by SuperScript
VILO cDNA Synthesis Kit (Invitrogen) according to the manufacturer’
instructions. qRT-PCR was performed in a C1000 Thermal Cycler
(Bio-Rad) with real-time detection of fluorescence, using the KAPA
SYBR FAST Master Mix reagent (KAPA Biosystems). Mouse mitochon-
drial ribosomal protein L41 (mRPL41) was used as a standard for quan-
tification. Primer sequences (Sigma Genosys) are reported in Table 1.
Ratios of comparative concentrations of each mRNAwith respect to L41
mRNAwere then calculated and plotted as the average of three indepen-
dent reactions (technical replicates) obtained from each RNA. Expres-
sion analyses were performed using the CFX3 Manager (Bio-Rad)
software (Sgado` et al., 2013).
ELISA. Hippocampi (n  4–6 mice per experimental group) were
homogenized in a Tris buffer containing a protease inhibitor mix-
ture (150 mM NaCl, 25 mM Tris, 1% Triton X-100 pH 7.4, complete
Figure 3. Gene expression changes triggered by systemic LPS in the epileptic hippocampus. A, Microarray heat map of the 533 genes differentially expressed at both 4 and 24 h in the
hippocampus of LPS- versus saline-treated epileptic mice. A color code scale was used to show gene expression differences in logarithmic fold change units between the groups (blue represents
lowest expression; red representshigher expression).B, Overrepresentedgeneontology categoriesofgenesdifferentially expressed inthehippocampusofLPS-versussaline-treatedchronicallyepileptic
mice, at both4and24hafter treatment. Differentially expressedgenes (533 in total)were classifiedbyDAVID software, applyingBenjamini-correctedp value cutoff of 0.05. Themost significant categories are
displayed at the top of the graph to downward (p value, gray line) and gene number arranged horizontally by the length of the bars (gene counts, colored bars). KEGG PATH, PANTHERMF, and GOTERMMF
indicate the databases used for gene classification (KEGG, PantherMolecular Function, andGOtermMolecular Function, respectively; for details, seeMaterials andMethods).
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protease inhibitor mixture; Roche Diagnostics). Samples were centri-
fuged for 30min at 15,000 g, and supernatants assayed for total protein
content using a Pierce BCA protein assay kit (Thermo Fisher Scientific).
Cytokine levels in tissue and serum samples (n  4–6 mice per experi-
mental group, each sample in triplicate) were assessed using MSD mul-
tiplex kit for mouse proinflammatory cytokines (K15012B; Meso Scale
Discovery). CCL2 protein quantitation in blood and hippocampal ex-
tracts was performed using CCL2 ready-set-go ELISA kit (eBioscience),
according to the manufacturer’s instructions.
CCL2 mRNA in situ hybridization. Brains from 3 chronically epileptic
mice were rapidly removed and frozen on dry ice, 4 h after LPS challenge.
Coronal cryostat sections (20 m thick) were fixed in 4% PFA. Nonra-
dioactive in situ hybridization was performed as previously described
(Tripathi et al., 2009) using a mix containing a CCL2 (GenBank ID: NM
011333.1) digoxigenin-labeled riboprobe. Signal was detected by alkaline
phosphatase-conjugated anti-digoxigenin antibody followed by alkaline
phosphatase staining. The specificity of the results was confirmed by
the use of sense riboprobes (data not shown). Imageswere acquired using
a Zeiss Axio Observer z1 microscope.
Immunostaining. Immunohistochemical characterization of CCL2
and CCR2 protein expression was performed on brains from 3 chroni-
cally epileptic mice treated with LPS. Brains were fixed by transcardial
perfusion with 4% PFA followed by 1 h postfixation at 4°C, and coronal
sections (40 m thick) were cut on a vibratome. Serial sections at the
level of the dorsal hippocampus were incubated overnight with appro-
priate antibodies (all from Abcam: CCL2, 1:200 dilution; CCR2, 1:200
dilution; CD68, 1:400 dilution). Signals were revealed with biotin-
conjugated secondary antibody and streptavidin conjugated to appropri-
ate fluorophores (AlexaFluor-488/-594, Invitrogen). Images were
acquired using a Zeiss Axio Observer z1 microscope.
Immunoblotting. To assess NF-kB phosphorylation, hippocampal pro-
teins from LPS (n 4) and LPS	RS (n 6) treated mice were extracted
with lysis buffer (1% Triton X-100, 10% glycerol, 20 mM Tris HCl, pH 7.5,
150 mM NaCl, 10 mM EDTA, 1 g/ml leupeptin, 1 mg/ml aprotinin, 1 mM
PMSF, PhosSTOPRoche phosphatase inhibitorsmixture). Protein concen-
tration was determined through BCA protein assay kit (Euroclone). Equal
amounts of each sample (30 g) were separated on 4%–12% precast gels
(Invitrogen), transferred to nitrocellulose membranes, blocked, and then
incubatedwith primary antibody overnight at 4°C (p65, 1:1000, Cell Signal-
ing Technology; phospho p65 S536, 1:1000, Cell Signaling Technology; and
actin 1:8000, Sigma-Aldrich). Secondary antibodies (anti-rabbit Ly-Cor
IRDye800RD; anti-mouse Ly-Cor IRDye680RD) were used at 1:10,000 di-
lution for 1 h at room temperature.
Themembranes were dried overnight in the dark at room temperature
and the signal was measured using an Odyssey CLx-Infrared Imaging
System. The signal intensity of immunoblotting bands was quantified
using iStudio software. Data are mean SEM.
Statistical analyses. For EEG experiments, statistical analysis was per-
formed by two-way repeated-measures ANOVA followed by Holm–
Sidak test for post hoc comparisons. Two-way ANOVA followed by
Tukey test was used for comparing gene expression at 4/24 h following
LPS/saline treatment. One-way ANOVA (followed by Dunn’s or Holm–
Sidak test) was used for comparing mean seizure duration and cytokine/
chemokine concentrations in blood and hippocampi. Differences
Figure 4. CCL2 and other inflammatory genes are upregulated in the hippocampus of LPS-treated epileptic mice. qRT-PCR validation of microarray experiments; plots represent the mRNA
expression of 9 inflammatory genes differentially expressed (upregulated) in the hippocampus of LPS-treated epileptic mice. Values are plotted as the fold increase in LPS- versus saline-treated
chronically epileptic mice (LPS/SAL ratio). CCL2 mRNA was 10-fold upregulated in LPS-treated epileptic hippocampus 4 h after LPS administration, with a significant decrease of 44.5% at 24 h
(two-way ANOVA followed by Tukey’s test, p 0.001). *p 0.05; ***p 0.001.
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between two groups were assessed with Student’s t test because our data
were normally distributed. For microarray data analysis, DAVID (http://
david.abcc.ncifcrf.gov) was used to assess for functional categories over-
represented in the differentially expressed 533 common genes between 4
and 24 h dataset. Pairwise comparisons of qRT-PCR and immunoblot-
ting data were assessed by a two-tailed Student’s t test. Level of signifi-
cance was set at p 0.05.
Results
Systemic inflammation enhances spontaneous seizures
MTLE was induced by unilateral injection of KA into the adult
mouse hippocampus (Riban et al., 2002; Antonucci et al., 2008).
All experiments were conducted during the chronic phase of ep-
ilepsy (i.e., starting from2weeks after KA), when the injected side
presents typical hippocampal sclerosis (Fig. 1A), and EEG re-
cordings show frequent SRSs, interictal clusters, and isolated
spikes (Fig. 1B).
We first examined the impact of a systemic inflammatory chal-
lenge on seizure activity. Baseline SRS were recorded for 4–5 d be-
fore intraperitoneal treatment with LPS (100g/kg) or saline (SAL)
as control. EEG recordings were performed 2–4 h after systemic
challenge (i.e., when the behavioral response to LPS is highest, Teel-
ing et al., 2007) and at 24 h.We found that injection of saline had no
effect on SRS at either time point, whereas injection of LPS clearly
increased seizure incidence within 4 h (two-way repeated-measures
ANOVA followed by Holm–Sidak test, p 0.05; Fig. 2A,B). Total
time spent in ictal and interictal activity was also significantly in-
creasedbyLPS(p0.05; Fig. 2C,E). Interestingly, the inflammatory
challengedidnot impact onmean seizureduration and frequencyof
isolated spikes (one way ANOVA, p 0.6; Fig. 2D,F). LPS effects
were transient, as mice recorded 24 h after treatment showed a re-
turn to the baseline, pre-LPS level of seizures and interictal dis-
charges (post-ANOVAHolm–Sidak test, p 0.05; Fig. 2B,C,E).
CCL2 upregulation in the epileptic hippocampus
following LPS
We then performed a microarray analysis to investigate the gene
expression pathways activated by LPS in KA-injected hip-
pocampi. To this purpose, we compared the transcriptomic
profile of chronically epileptic hippocampi in LPS- versus saline-
treated mice. The expression profile of epileptic hippocampi
markedly differed between LPS- and saline-treated animals, at
both 4 and 24 h after treatment (Fig. 3A). A total of 533 genes
were differentially expressed in epileptic hippocampi at both 4
and 24 h after LPS, compared with saline-treated animals; path-
way analysis revealed that most of these differentially expressed
genes belong to chemokine/cytokine pathways (Fig. 3B).We next
used qRT-PCR to validate nine of these differentially expressed
genes. Compared with saline-treated epileptic mice, CCL2 and
IL-1 mRNA were 10-fold and 8-fold, respectively, upregulated
in LPS-treated epilepticmice 4 h after LPS administration, signif-
icantly decreasing at 24 h (two-way ANOVA followed by Tukey’s
test, p 0.0001; Fig. 4). CCL4mRNA was only 1.9-fold upregu-
Figure 5. Cytokine/chemokine concentrations in blood and hippocampus of epileptic and naivemice, 4 h after LPS/saline treatment.A,B, LPS increased the levels of CCL2 and IL-1 in the blood
of both epileptic and naive mice (one-way ANOVA, p 0.05). A, In the hippocampus, CCL2 expression was more robustly upregulated in epileptic versus naive mice (one-way ANOVA followed by
Holm–Sidak test, p 0.05). B, IL-1 showed a similar but nonsignificant trend (one way ANOVA followed by Dunn’s test p 0.05). C–E, TNF, interferon-, and IL-10 were upregulated in the
bloodof LPS-treatedmice (one-wayANOVA followedbyDunn’s test,p0.01), butno consistentmirror responsewasobserved inhippocampal samples of eithernaiveor epileptic animals (one-way
ANOVA, p 0.4). *p 0.05; **p 0.01.
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lated in LPS-treated mice at 4 h and returned to basal levels 24 h
after LPS administration (two-way ANOVA followed by Tukey’s
test, p  0.02). The chemokines CCL5, CCL12, and CXCL10
showed a stronger upregulation at 24 h with respect to 4 h (two-
way ANOVA followed by Tukey’s test, p  0.0001). The CCL2
receptor CCR2 as well as the Toll-like receptors TLR4 and TLR2
showed modest changes in LPS-treated mice (Fig. 4). Together,
the strong increase of CCL2 and IL-1 expression at the time of
LPS-induced seizure aggravation (4 h) points to a possible in-
volvement of these molecules in mediating LPS effects.
We then analyzedCCL2 and IL-1 protein levels 4 h following
LPS challenge (Fig. 5A,B) using ELISA. LPS increased CCL2 and
IL-1 levels in the blood of both epileptic and naive mice (Fig.
5A,B). Analysis of hippocampal samples revealed a strong “prim-
ing” effect, with CCL2 expression more robustly upregulated in
the hippocampus of epileptic versus naive mice (one-way
ANOVA followed byHolm–Sidak test, p 0.05; Fig. 5A). Similar
results were obtained for IL-1 in the blood, whereas IL-1 levels
did not differ significantly in the hippocampus of epileptic or
naivemice treatedwith LPS (Fig. 5B).Multiplex ELISA revealed a
robust upregulation of TNF, interferon-, and IL-10 in the
blood of LPS-treated mice, but increases in the brain were ex-
tremelymodest and independent of the epileptic phenotype (Fig.
5C–E). These data indicate selectivity in the “mirror” inflamma-
tory cascades triggered by a systemic challenge within the epilep-
tic brain, and a potential role of CCL2 in translating the CNS
effects of systemic inflammation.
We next examined the cell populations expressing CCL2 and
its receptor CCR2 in the epileptic hippocampus. CCL2mRNA in
situ hybridization and immunostaining indicated expression of
CCL2 in pyramidal neurons and dispersed granule cells of the
dentate gyrus following LPS challenge (Fig. 6A–C). Several small,
likely glial cells of stratum oriens, stratum radiatum, stratum
lacunosum moleculare, and hilus were also labeled (Fig. 6A,B).
Immunohistochemical localization of CCR2 was found predom-
inantly in activated microglia/macrophages within the sclerotic
tissue (Fig. 6D,E), consistent with a role for CCR2 in microglia
and monocyte recruitment (Shi and Pamer, 2011; Cunningham,
2013).
Interference with CCL2/CCR2 signaling abrogates LPS-
induced seizure enhancement
We next asked whether interfering with CCL2 would prevent the
enhancement of chronic seizures following systemic LPS treat-
ment. We first used the anti-inflammatory drug bindarit that
preferentially inhibits transcription of the monocyte chemoat-
tractant subfamily of CC chemokines, includingCCL2 (Mirolo et
al., 2008; Ge et al., 2012; Mora et al., 2012). We recorded baseline
EEG seizure activity; then epileptic animals received daily intra-
peritoneal injections of bindarit (100 mg/kg) (Ge et al., 2012) or
vehicle solution (MC) for 4 d. EEG recording sessions were per-
formed 30 min after the third and the fourth daily injection. At
the end of the recording session on the fourth day, mice were
challenged with LPS and recorded 2–4 h later (Fig. 7A). Record-
ings performed before LPS challenge showed that seizure fre-
quency and total time spent in seizures were unaltered by either
bindarit or vehicle with respect to baseline (two-way repeated-
measures ANOVA followed by Holm–Sidak test, p  0.05; Fig.
7B,C). Importantly, LPS triggered the expected seizure upregu-
lation in controls but failed to do so in animals treated with
bindarit (two-way repeated-measures ANOVA, bindarit vs con-
trol, 2–4 h after LPS, p 0.01; Fig. 7B,C).Mean seizure duration
following LPS administration was unaffected by either bindarit
or vehicle treatment (one-way ANOVA, p  0.3; Fig. 7D). The
LPS-induced increase in interictal discharges was also abolished
by bindarit (Fig. 7E), whereas the number of isolated interictal
spikes did not vary between bindarit- and vehicle-treated epilep-
tic mice (Fig. 7F). Thus, treatment with bindarit abolishes the
seizure-enhancing effect of systemic inflammation.
To probe the effects of bindarit at the molecular level, we
collected epileptic hippocampi and blood samples frombindarit-
and vehicle-treated mice, 4 h after LPS delivery. ELISA showed
that CCL2 protein was reduced by 77.4% in blood of bindarit-
treated animals, comparedwith controlmice (t test, p 0.01; Fig.
8A). qRT-PCR confirmed this reduction at the mRNA level (p
0.001; Fig. 8B). In blood samples, bindarit also dampened CCL5
Figure 6. Cellular localization of CCL2 and CCR2 in the sclerotic hippocampus after LPS.A–C,
CCL2mRNA(A,B) andprotein (C) stainingon representative sections fromthedorsal hippocam-
pusof anepilepticmouse, 4hafter LPS. CCL2 staining is present inpyramidal neurons, dispersed
granule cells of thedentategyrus (A,B, arrowhead) and several small, likelyglial cells of stratum
oriens, stratum radiatum (A, B, arrows), stratum lacunosum moleculare, and hilus. Details of
labeled cells are shown in B. Left, CA1 stratum radiatum. Right, Dentate granule cells. Scale
bars:A, 200m;B, 40m;C, 600m.D, Immunostainings of CCR2on representative sections
from the epileptic (left) and contralateral (right) hippocampus, 4 h after LPS. CCR2 staining
is mainly restricted to the CA1 subfield and dentate gyrus of the epileptic hippocampus and is
absent from the contralateral side. Scale bar, 600 m. E, Immunostainings of CCR2 (green),
CD68 (red), and their colocalization (yellow)ona representative section fromtheCA1 subfieldof
an epileptic mouse, 4 h after LPS. Expression of CCR2 in activated microglia/macrophages, as
indicated by CCR2/CD68 colocalization (yellow), is evident in high-magnification figures shown
in insets. Scale bar: 150m; insets, 30m.
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mRNA levels (t test, p  0.01) and robustly increased CCR2
mRNA (t test, p 0.0017), suggesting a compensatory response
to pharmacological suppression of CCL2 availability (Fig. 8B).
No statistically significant differences were found for IL-1 and
TLR2mRNA expression levels in blood following bindarit treat-
ment (Fig. 8B). qRT-PCR revealed a more widespread reduction
of proinflammatory pathways in the hippocampus of bindarit-
treated mice: CCL2, CCL5, IL1, and TLR2 mRNAs were ro-
bustly downregulated, whereas CCR2 mRNA expression was
increased (t test, p 0.01 for all comparisons; Fig. 8C).
CCL2 acts mainly through the G-protein-coupled receptor
CCR2 to exert its biological effects (Semple et al., 2010). There-
fore, we tested the effects of a potent and selective CCR2
antagonist, RS102895 (Hung et al., 2013; Ren et al., 2015) on
LPS-induced seizures (Fig. 9A). We found that systemic
RS102895 treatment, but not vehicle, abolished the increase of
epileptiform discharges triggered by LPS (t test, p  0.01; Fig.
9B). The enhancement of interictal activity was also counteracted
by RS102895 (t test, p  0.01; Fig. 9C). To examine molecular
correlates of LPS-induced CCR2 signaling, we tested whether
phosphorylation of the transcription factor NF-B (Yang et al.,
2003; Mora et al., 2012) is impacted by RS102895. We used im-
munoblotting to quantify levels of total (p65) and phosphory-
lated NF-B (S536 phospho p65) in sclerotic hippocampi from
LPS	vehicle and LPS	RS102895mice (Fig. 9D).We found that,
although total levels of p65 were comparable in the two groups
(t test, p  0.76), RS102895 treatment significantly reduced the
fraction of phosphorylated p65 (t test, p 0.01; Fig. 9E).
To selectively interfere with CCL2 signaling within the ep-
ileptic focus, we injected a CCL2 neutralizing antibody (or
control IgG) directly into the hippocampus of chronic epilep-
tic animals 30 min before the LPS challenge (Fig. 10A). As
expected, LPS increased SRS frequency and total time spent in
ictal activity in control-injected hippocampi (Fig. 10B,C).
Blocking CCL2 locally within the hippocampus completely
abolished the LPS-induced increase in seizures (two-way
ANOVA followed by Holm–Sidak test, control IgG vs anti-
CCL2, p  0.01; Fig. 10B,C), whereas mean seizure duration
was unaffected (Fig. 10D). LPS-mediated increase of total time
spent in interictal activity was also prevented by anti-CCL2
Figure 7. Treatmentwith bindarit abolishes the seizure-enhancing effect of LPS.A, Experimental protocol. After baseline assessment of SRS, animalswere treated dailywith either bindarit (Bin)
or vehicle (MC) and injected systemicallywith LPSon the fourthday.B,C, Frequency of seizures and total time spent in ictal activity per 10minof recording (normalized to thebaselineperiod). Before
LPS treatment (3–4 d), seizure frequency and total time spent in seizures were unaltered by either bindarit or vehicle with respect to baseline (two-way repeated-measures ANOVA followed by
Holm–Sidak test, p 0.05). After LPS challenge (post LPS), seizure frequency and total duration of ictal activity were significantly higher in controls with respect to bindarit-treated animals ( p
0.01). D, Mean seizure duration in bindarit (Bin) and control animals (MC) before (baseline) and after LPS administration. Mean seizure duration was unaffected by LPS	 bindarit or LPS	MC
treatment (one-wayANOVA,p0.7).E, Total time spent in interictal activity per 10minof recordings (normalized to thebaselineperiod). Before LPS treatment (3–4d), total time spent in interictal
activitywas unalteredby either bindarit or vehiclewith respect to baseline (two-way repeated-measures ANOVA,p0.05). After LPS (2–4hafter treatment), the total duration of interictal activity
was significantly higher in controls with respect to bindarit-treated animals (two-way repeated-measures ANOVA, p 0.001). F, Number of isolated spikes per 10min of recording (normalized to
the baseline period). Bindarit- and vehicle-treated epilepticmice showed the same range of isolated spike frequency 2–4 h after LPS administration (two-way repeated-measures ANOVA followed
by Holm–Sidak test, p 0.3). **p0.01; ***p 0.001.
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injection (p 0.05; Fig. 10E), whereas the number of isolated
interictal spikes did not differ between anti-CCL2-treated and
control epileptic mice (Fig. 10F ).
Discussion
In this article, we exploited systemic inflammation to perform
a molecular screening for the identification of novel inflam-
matory mediators involved in seizure precipitation. We first
examined the functional effect of a LPS challenge in chroni-
cally epileptic animals. As a model of chronic seizures, we
chose a well-established mouse model based on a single intra-
hippocampal injection of KA, which induces nonconvulsive
status epilepticus (SE) followed by the occurrence of SRS and
extensive hippocampal damage (Riban et al., 2002; Gouder et
al., 2004; Antonucci et al., 2008, 2009; Maroso et al., 2010;
Pallud et al., 2011). Importantly, intracerebral KA administra-
tion induces blood–brain barrier disruption and triggers local
inflammatory responses (Zattoni et al., 2011). We found that a
systemic inflammatory challenge exacerbates the epileptic
phenotype, enhancing SRS frequency in KA-injected, chroni-
cally epileptic mice. This is in agreement with previous studies
showing a proconvulsant effect of a systemic inflammatory
stimulus (Sayyah et al., 2003; Galic et al., 2008; Riazi et al.,
2008; Friedman and Dingledine, 2011; Zattoni et al., 2011; de
Vries et al., 2012; Gyo¨rffy et al., 2014; Marchi et al., 2014), such
as LPS (Sayyah et al., 2003; Galic et al., 2008; Gyo¨rffy et al.,
2014). In particular, LPS administration produces convul-
sions in rats treated with a normally subconvulsant dose of KA
(Heida et al., 2005). Systemic LPS also enhances baseline hip-
pocampal excitability and increases progression of rapid kin-
dling, an effect that is counteracted by neutralization of IL-1
(Auvin et al., 2010). In addition, a growing body of evidence
indicates that pilocarpine, one of the most widely used pro-
convulsant agents, does not require brain access to induce SE,
apparently acting as a peripheral proinflammatory agent that
triggers seizures (Marchi et al., 2014). Our data expand this
notion, demonstrating, for the first time, that a systemic in-
flammatory challenge is able to worsen SRS occurrence in the
intracerebral KA model of MTLE. The present data also add a
novel mechanistic insight because LPS increased frequency
of ictal events with no effect on seizure duration. Thus, pe-
ripheral inflammation appears to target specifically the
mechanisms responsible for seizure onset, leaving seizure ter-
mination unaffected.
Microarray and protein analysis provided us with an overview
of molecular factors regulated by LPS challenge in chronic epi-
leptic animals. Among these factors, CCL2 emerged as a potential
mediator of the functional effects of LPS. CCL-2mRNA was up-
regulated at the time of LPS-induced seizure aggravation (4 h)
and significantly decreased at the time at which seizure frequency
returned to the baseline (24 h). We found that IL-1mRNA also
showed a similar behavior, in line with the well-known procon-
vulsant actions of this cytokine (Vezzani et al., 2013). CCL2 pro-
tein levels were rapidly upregulated by LPS both in the blood and
in the sclerotic hippocampus. Interestingly, we found a signifi-
cantly more robust rise of CCL2 levels in the epileptic versus
naive hippocampus, likely due to a “priming” effect as a conse-
quence of the KA-induced neurodegeneration (Perry and Hol-
mes, 2014). Given the alterations in the blood–brain barrier
typical of the KA-lesioned hippocampus (Zattoni et al., 2011), we
cannot exclude the possibility that LPS-induced CCL2 upre-
gulation is a consequence of blood–brain barrier disruption
and associated cellular recruitment. However, several other in-
flammatory mediators, such as TNF, interferon-, and IL-10,
were upregulated by LPS only in blood but not in hippocampus
(Fig. 5), indicating selectivity of the “mirror” response within the
epileptic focus. Other studies using much higher doses of LPS
(i.e., 2 mg/kg) found a more generalized increase in the expres-
sion of various proinflammatory genes in the hippocampus (Ca-
zareth et al., 2014). Together, our data show that LPS triggers an
exaggerated CCL2 upregulation in the epileptic brain, tightly
coupled to seizure precipitation.
To test the functional role of CCL2 in inflammation-induced
seizures, we used systemic delivery of bindarit, an indazolic deriva-
tive that acts as a powerfulmodulator of the inflammatory response.
Figure8. Effect of bindarit on CCL2, CCL5, CCR2, IL-1, and TLR2 expression.A, CCL2 protein
levels were reduced by77.4% in serum of bindarit-treated animals compared with control
mice (t test, p 0.01), 4 h after LPS challenge. B, C, CCL2, CCL5, CCR2, IL-1, and TLR2mRNA
levelsmeasured by qRT-PCR in blood (B) and in the hippocampus (C) of control (MC) or bindarit
(Bin) treated epileptic mice, 4 h after LPS injection. In the blood, bindarit dampened CCL2 and
CCL5mRNA levels (t test, p 0.01) and increased CCR2 expression (t test, p 0.01; B). In the
hippocampus, bindarit downregulated CCL2, CCL5, IL- 1, and TLR2 mRNAs while increasing
CCR2mRNA (t test, p 0.0001 for CCL2, p 0.02 for CCL5, p 0.0001 for IL-1, p 0.0005
for TLR2, and p 0.0001 for CCR2; C). *p 0.05; **p 0.01; ***p 0.001.
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Inparticular, it isknownthatbindarit inhib-
its transcription of monocyte chemoattrac-
tant subfamily of CC chemokines (Cioli et
al., 1992;Miroloet al., 2008), and this is con-
sistent with the decreased levels of both
CCL2 and CCL5 mRNA in the blood and
hippocampus of bindarit-treated animals
(Fig. 8B,C). Interestingly, ourdata suggest a
compensatoryupregulationof theCCL2 re-
ceptor (CCR2) at both the peripheral and
central levels (Fig. 8B,C), indicating cellular
supersensitivity toCCL2 following itsdeple-
tion. It is also interesting to note that the
hippocampus of bindarit-treated mice
displayeda reducedexpressionof additional
inflammatory factors (i.e., IL-1 and
TLR2), whose levels were unaffected in the
blood. These data suggest that chronic
downregulation of CCL2 by bindarit makes
brain structures less responsive to the LPS
challenge. This is consistent with the notion
that CCL2 can primemicroglial cells (Bhat-
tacharyya et al., 2002; Rankine et al., 2006;
Perry and Holmes, 2014). Indeed, CCL2
modulates the responsiveness of microglia
to acute inflammation, and CCL2/mice
display a dampened synthesis of proinflam-
matory cytokines (e.g., IL-1, TNF) fol-
lowing intraparenchymal LPS (Rankine et
al., 2006).
To further corroborate the results ob-
tained with systemic depletion of CCL2, we
used parenteral administrations of a potent
and selective CCR2 antagonist, RS102895,
which has been previously used to interfere
with CCR2 signaling in the brain (Hung et
al., 2013; Ren et al., 2015). We found that
administrationofRS102895blocked the en-
hancement of epileptiform activity and the
phosphorylation of NF-B (p65 subunit)
induced by LPS. These data suggest the po-
tential of CCR2 antagonists for the treat-
ment of inflammation-induced seizures. We also targeted CCL2
directly into the epileptic focus, using blocking antibodies delivered
at the time of LPS delivery. Results were clear in indicating amarked
suppressionof theLPS-induced seizure enhancementwith the func-
tionally blocking, but not control, antibodies. In conclusion, both
systemic and local interference with CCL2/CCR2 signaling
yields potent anticonvulsant effects following systemic in-
flammation. These data show a previously unrecognized role
for CCL2 in mediating seizure upregulation following sys-
temic inflammation.
Severalmechanismsmay account for the seizure-promoting action
of CCL2. First, CCL2may exert direct effects on neuronal excitability.
Indeed,CCL2alters electrophysiological properties andCa2	 signaling
in cerebellar neurons (van Gassen et al., 2005), reduces inhibitory re-
sponses in spinal cord neurons (Gosselin et al., 2005), and potentiates
excitatorypostsynapticcurrents intheSchaffercollateralpathwayofthe
hippocampus in vitro (Zhou et al., 2011). These latter effects aremedi-
ated by activation of the p38 MAP kinase pathway (Cho and Gruol,
2008). Second, CCL2 may also increase seizure frequency indirectly,
actingas apriming stimulus for the synthesis ofotherproinflammatory
factors inthebrain.Asdescribedabove,depletionofCCL2mayresult in
lowered synthesis and signalingof IL-1, whose involvement in seizure
precipitation is well documented (Balosso et al., 2008; Maroso et al.,
2011; Vezzani et al., 2011). Here, we have demonstrated that CCR2 is
expressed in activatedmicroglia/macrophages within the sclerotic hip-
pocampus (Fig. 6). As activated microglial cells are prominently in-
volvedintheproductionandreleaseofIL-1 inepileptictissue(Vezzani
et al., 1999), these data suggest that CCL2 may increase seizures via
IL-1.Thus, theCCL2pathwaymayactasamasterregulatorof inflam-
matory processes in the epileptic brain by both directly promoting hy-
perexcitability and regulating the activity of downstream inflammatory
effectors. Finally, CCL2 might also be involved in neuropathological
changes that accompany seizures, as indicated by a recent study (Hung
et al., 2013). After pilocarpine-induced SE, CCL2 mRNA and protein
were significantly upregulated in the dentate gyrus, whereas the CCL2
receptor CCR2 was expressed in ectopic progenitors of hilar neurons.
Systemic blockade of CCR2with RS102895 attenuated the ectopicmi-
grationofneuronalprogenitors intothehilus, indicatingacrucialroleof
CCL2/CCR2 interaction in neuronal migration following seizures
(Hung et al., 2013).
CCL2 elevations have been previously demonstrated in the brain
of patientswith intractable epilepsy (Choi et al., 2009) and following
Figure 9. Systemic delivery of a CCR2 receptor antagonist prevents the LPS-induced enhancement of epileptic activity. A,
Experimental protocol.B, Frequency of epileptiformdischarges (normalized to the baseline period) in animals treatedwith vehicle
(veh) or RS102895 (RS), 2– 4 h after LPS challenge. RS102895 prevents the enhancement of epileptic activity (t test, p 0.01). C,
Total time spent in interictal activity (normalized to the baseline period) in LPS-injected animals treatedwith vehicle or RS102895.
CCR2 antagonism prevents the LPS-induced increase in interictal discharges (t test, p 0.01). D, Immunoblotting showing the
levels of total p65, phosphorylated (phospho) p65, and-actin (loading control) in the sclerotic hippocampus of a representative
LPS	vehicle (veh) and LPS	RS102895 (RS)mouse. E, Quantification of the immunoblotting data. The statistical analysis (t test,
p 0.01) indicates consistent reduction of the fraction of phosphorylated p65 in LPS	RS102895 (RS) mice compared with
LPS	vehicle (veh). **p 0.01.
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experimental seizures in animals (Foresti et al., 2009).Here, we pro-
vide the first demonstration of a key functional role for CCL2 in
seizureprecipitation.Drugs interferingwithCCL2 signaling are cur-
rently under development for several inflammatory brain disorders
(Semple et al., 2010) and may be tested in epileptic syndromes that
remain resistant to currently available medications.
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